Healthcare provider profile · identity verified

Laura J Head, PAC

Physician Assistant · BANGOR, ME · NPI 1417297110

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Eliquis	Apixaban	225	40
Levothyroxine Sodium	Levothyroxine Sodium	195	47
Furosemide	Furosemide	179	38
Metoprolol Succinate	Metoprolol Succinate	159	35
Atorvastatin Calcium	Atorvastatin Calcium	148	58
Gabapentin	Gabapentin	125	36
Pantoprazole Sodium	Pantoprazole Sodium	122	38
Warfarin Sodium	Warfarin Sodium	105	suppressed
Potassium Chloride	Potassium Chloride	88	30
Lisinopril	Lisinopril	85	27
Duloxetine Hcl	Duloxetine Hcl	84	13
Jardiance	Empagliflozin	82	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	77	24
Famotidine	Famotidine	75	11
Bumetanide	Bumetanide	71	12
Venlafaxine Hcl Er	Venlafaxine Hcl	69	suppressed
Amlodipine Besylate	Amlodipine Besylate	67	26
Trulicity	Dulaglutide	64	suppressed
Buspirone Hcl	Buspirone Hcl	60	11
Sertraline Hcl	Sertraline Hcl	60	18
Trazodone Hcl	Trazodone Hcl	53	16
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	52	suppressed
Omeprazole	Omeprazole	51	26
Hydralazine Hcl	Hydralazine Hcl	50	17
Metformin Hcl	Metformin Hcl	49	13
Spironolactone	Spironolactone	48	11
Diclofenac Sodium	Diclofenac Sodium	47	suppressed
Farxiga	Dapagliflozin Propanediol	46	suppressed
Myrbetriq	Mirabegron	46	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	45	12
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	41	suppressed
Levetiracetam	Levetiracetam	41	suppressed
Losartan Potassium	Losartan Potassium	40	18
Xarelto	Rivaroxaban	40	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	39	suppressed
Finasteride	Finasteride	37	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	34	suppressed
Clopidogrel	Clopidogrel Bisulfate	33	11
Ropinirole Hcl	Ropinirole Hcl	33	suppressed
Allopurinol	Allopurinol	31	suppressed
Divalproex Sodium	Divalproex Sodium	31	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	30	suppressed
Pravastatin Sodium	Pravastatin Sodium	30	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	29	suppressed
Fluticasone Propionate	Fluticasone Propionate	29	13
Metoprolol Tartrate	Metoprolol Tartrate	29	23
Montelukast Sodium	Montelukast Sodium	29	suppressed
Atenolol	Atenolol	27	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Simvastatin	Simvastatin	27	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	26	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	26	suppressed
Mirtazapine	Mirtazapine	26	suppressed
Prednisone	Prednisone	26	17
Tramadol Hcl	Tramadol Hcl	26	suppressed
Humalog	Insulin Lispro	25	suppressed
Linzess	Linaclotide	24	suppressed
Nystatin	Nystatin	24	12
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	22	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	22	suppressed
Incruse Ellipta	Umeclidinium Bromide	22	suppressed
Lovastatin	Lovastatin	22	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	22	14
Aripiprazole	Aripiprazole	21	suppressed
Carbamazepine Er	Carbamazepine	21	suppressed
Carvedilol	Carvedilol	21	suppressed
Digoxin	Digoxin	20	suppressed
Entresto	Sacubitril/Valsartan	20	suppressed
Morphine Sulfate	Morphine Sulfate	20	suppressed
Oxycodone Hcl	Oxycodone Hcl	20	14
Pregabalin	Pregabalin	20	suppressed
Carbamazepine	Carbamazepine	19	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Topiramate	Topiramate	19	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Ondansetron Odt	Ondansetron	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	16	suppressed
Alendronate Sodium	Alendronate Sodium	16	suppressed
Metformin Hcl Er	Metformin Hcl	16	suppressed
Ranolazine Er	Ranolazine	16	suppressed
Doxepin Hcl	Doxepin Hcl	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Prazosin Hcl	Prazosin Hcl	15	suppressed
Torsemide	Torsemide	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Insulin Lispro	Insulin Lispro	14	suppressed
Insulin Lispro Junior Kwikpen	Insulin Lispro	14	suppressed
Latanoprost	Latanoprost	14	suppressed
Metolazone	Metolazone	14	suppressed
Repatha Sureclick	Evolocumab	14	suppressed
Steglatro	Ertugliflozin Pidolate	14	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Diltiazem 24hr Er (La)	Diltiazem Hcl	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Risperidone	Risperidone	13	suppressed
Spiriva Handihaler	Tiotropium Bromide	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Cephalexin	Cephalexin	12	suppressed
Dulera	Mometasone/Formoterol	12	suppressed
Novolog	Insulin Aspart	12	suppressed
Baclofen	Baclofen	11	suppressed
Balsalazide Disodium	Balsalazide Disodium	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Metronidazole	Metronidazole	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Olanzapine	Olanzapine	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Roflumilast	Roflumilast	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error